{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:37:14Z","timestamp":1794375434081,"version":"4.9.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["GM131729"],"award-info":[{"award-number":["GM131729"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["HL139994"],"award-info":[{"award-number":["HL139994"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","award":["GT12053"],"award-info":[{"award-number":["GT12053"]}],"id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["HATFUL19GO"],"award-info":[{"award-number":["HATFUL19GO"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1038\/s41591-021-01403-9","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T12:03:27Z","timestamp":1625745807000},"page":"1357-1361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":203,"title":["Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3666-711X","authenticated-orcid":false,"given":"Rebekah M.","family":"Dedrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2944-5076","authenticated-orcid":false,"given":"Krista G.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan A.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asli","family":"Bahadirli-Talbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailey E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0275-8037","authenticated-orcid":false,"given":"Cheng Ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa C.","family":"Ruppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Parrish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6705-6821","authenticated-orcid":false,"given":"Graham F.","family":"Hatfull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4521-397X","authenticated-orcid":false,"given":"Keira A.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"key":"1403_CR1","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41579-020-0331-1","volume":"18","author":"MD Johansen","year":"2020","unstructured":"Johansen, M. D., Herrmann, J.-L. & Kremer, L. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat. Rev. Microbiol. 18, 392\u2013407 (2020).","journal-title":"Nat. Rev. Microbiol."},{"key":"1403_CR2","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","volume":"175","author":"DE Griffith","year":"2007","unstructured":"Griffith, D. E. et al. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175, 367\u2013416 (2007).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1403_CR3","doi-asserted-by":"crossref","first-page":"e02189-16","DOI":"10.1128\/AAC.02189-16","volume":"61","author":"H Choi","year":"2017","unstructured":"Choi, H. et al. Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium massiliense lung disease. Antimicrob. Agents Chemother. 61, e02189-16 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1403_CR4","doi-asserted-by":"crossref","first-page":"e01146-17","DOI":"10.1128\/AAC.01146-17","volume":"61","author":"H Choi","year":"2017","unstructured":"Choi, H. et al. Clinical characteristics and treatment outcomes of patients with acquired macrolide-resistant Mycobacterium abscessus lung disease. Antimicrob. Agents Chemother. 61, e01146-17 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1403_CR5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.chom.2019.01.014","volume":"25","author":"KE Kortright","year":"2019","unstructured":"Kortright, K. E., Chan, B. K., Koff, J. L. & Turner, P. E. Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe 25, 219\u2013232 (2019).","journal-title":"Cell Host Microbe"},{"key":"1403_CR6","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nrmicro3564","volume":"13","author":"GPC Salmond","year":"2015","unstructured":"Salmond, G. P. C. & Fineran, P. C. A century of the phage: past, present and future. Nat. Rev. Microbiol. 13, 777\u2013786 (2015).","journal-title":"Nat. Rev. Microbiol."},{"key":"1403_CR7","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","volume":"25","author":"RM Dedrick","year":"2019","unstructured":"Dedrick, R. M. et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat. Med. 25, 730\u2013733 (2019).","journal-title":"Nat. Med."},{"key":"1403_CR8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4049\/jimmunol.76.3.200","volume":"76","author":"NK Jerne","year":"1956","unstructured":"Jerne, N. K. & Avegno, P. The development of the phage-inactivating properties of serum during the course of specific immunization of an animal: reversible and irreversible inactivation. J. Immunol. 76, 200\u2013208 (1956).","journal-title":"J. Immunol."},{"key":"1403_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.chom.2017.06.018","volume":"22","author":"DR Roach","year":"2017","unstructured":"Roach, D. R. et al. Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen. Cell Host Microbe 22, 38\u201347.e4 (2017).","journal-title":"Cell Host Microbe"},{"key":"1403_CR10","unstructured":"Hodyra-Stefaniak, K. et al. Mammalian host-versus-phage immune response determines phage fate in vivo. Sci. Rep. 5, 14802 (2015)."},{"key":"1403_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/B978-0-12-394438-2.00002-5","volume":"83","author":"A G\u00f3rski","year":"2012","unstructured":"G\u00f3rski, A. et al. Phage as a modulator of immune responses: practical implications for phage therapy. Adv. Virus Res. 83, 41\u201371 (2012).","journal-title":"Adv. Virus Res."},{"key":"1403_CR12","doi-asserted-by":"publisher","first-page":"ofaa389","DOI":"10.1093\/ofid\/ofaa389","volume":"7","author":"S Aslam","year":"2020","unstructured":"Aslam, S. et al. Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States. Open Forum Infect. Dis. 7, ofaa389 (2020).","journal-title":"Open Forum Infect. Dis."},{"key":"1403_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1089\/vim.2013.0128","volume":"27","author":"M \u0141usiak-Szelachowska","year":"2014","unstructured":"\u0141usiak-Szelachowska, M. et al. Phage neutralization by sera of patients receiving phage therapy. Viral Immunol. 27, 295\u2013304 (2014).","journal-title":"Viral Immunol."},{"key":"1403_CR14","first-page":"741","volume":"81","author":"C Kamme","year":"1973","unstructured":"Kamme, C. Antibodies against staphylococcal bacteriophages in human sera. I. Assay of antibodies in healthy individuals and in patients with staphylococcal infections. Acta Pathol. Microbiol. Scand. B Microbiol. Immunol. 81, 741\u2013748 (1973).","journal-title":"Acta Pathol. Microbiol. Scand. B Microbiol. Immunol."},{"key":"1403_CR15","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1111\/ajt.15503","volume":"19","author":"S Aslam","year":"2019","unstructured":"Aslam, S. et al. Early clinical experience of bacteriophage therapy in 3 lung transplant recipients. Am. J. Transplant. 19, 2631\u20132639 (2019).","journal-title":"Am. J. Transplant."},{"key":"1403_CR16","doi-asserted-by":"crossref","unstructured":"Schooley, R. T. et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob. Agents Chemother. 61, e00954-17 (2017).","DOI":"10.1128\/AAC.00954-17"},{"key":"1403_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1473-3099(18)30482-1","volume":"19","author":"P Jault","year":"2019","unstructured":"Jault, P. et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1\/2 trial. Lancet Infect. Dis. 19, 35\u201345 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"1403_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/cid\/ciy947","volume":"69","author":"L El Haddad","year":"2019","unstructured":"El Haddad, L., Harb, C. P., Gebara, M. A., Stibich, M. A. & Chemaly, R. F. A systematic and critical review of bacteriophage therapy against multidrug-resistant ESKAPE organisms in humans. Clin. Infect. Dis. 69, 167\u2013178 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"1403_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1146\/annurev-virology-122019-070009","volume":"7","author":"GF Hatfull","year":"2020","unstructured":"Hatfull, G. F. Actinobacteriophages: genomics, dynamics, and applications. Annu. Rev. Virol. 7, 37\u201361 (2020).","journal-title":"Annu. Rev. Virol."},{"key":"1403_CR20","doi-asserted-by":"crossref","first-page":"e03431-20","DOI":"10.1128\/mBio.03431-20","volume":"12","author":"RM Dedrick","year":"2021","unstructured":"Dedrick, R. M. et al. Mycobacterium abscessus strain morphotype determines phage susceptibility, the repertoire of therapeutically useful phages, and phage resistance. MBio 12, e03431-20 (2021).","journal-title":"MBio"},{"key":"1403_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.virol.2012.09.026","volume":"434","author":"D Jacobs-Sera","year":"2012","unstructured":"Jacobs-Sera, D. et al. On the nature of mycobacteriophage diversity and host preference. Virology 434, 187\u2013201 (2012).","journal-title":"Virology"},{"key":"1403_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.tube.2019.01.002","volume":"115","author":"RM Dedrick","year":"2019","unstructured":"Dedrick, R. M. et al. Mycobacteriophage ZoeJ: a broad host-range close relative of mycobacteriophage TM4. Tuberculosis (Edinb.) 115, 14\u201323 (2019).","journal-title":"Tuberculosis (Edinb.)"},{"key":"1403_CR23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1365-2958.1993.tb01131.x","volume":"7","author":"GF Hatfull","year":"1993","unstructured":"Hatfull, G. F. & Sarkis, G. J. DNA sequence, structure and gene expression of mycobacteriophage L5: a phage system for mycobacterial genetics. Mol. Microbiol. 7, 395\u2013405 (1993).","journal-title":"Mol. Microbiol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01403-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01403-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01403-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T06:12:26Z","timestamp":1672726346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01403-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1403"],"URL":"https:\/\/doi.org\/10.1038\/s41591-021-01403-9","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]},"assertion":[{"value":"10 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.A.N. has received consulting fees from AstraZeneca. G.F.H. is a compensated consultant for Janssen. K.A.C. has received consulting fees from Insmed, Hillrom and Merck. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}